Human Urocortin II (Urocortin Related Peptide, URP) is identical
with Stresscopin Related Peptide (SRP) (6-43)-NH2 (Human).
References:
Lewis, K. et al. Proc. Natl. Acad.
Sci. USA 98, 7570-7575, 2001 (June 19)
Hsu, S.Y. & Hsueh, A.J.W. Nature Medicine, 7 605-611, 2001
Review by Jun Yang on June 21, 2001
Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing
Factor Receptor, Decreases Feeding and Drinking in the Rat
Corticotropin-releasing factor (CRF) has been hypothesized to modulate
consummatory behavior through the Type 2 CRF (CRF(2)) receptor.
However, behavioral functions subserved by the CRF(2) receptor remain
poorly understood. Recently, human urocortin II (hUcn II), a selective
CRF(2) receptor agonist, was identified. To study the effects of
this neuropeptide on ingestive behavior, we examined the effects
of centrally infused hUcn II (i.c.v. 0, 0.01, 0.1, 1.0, 10.0 &mgr;g)
on the microstructure of nose-poke responding for food and water
in nondeprived, male rats. Malaise-inducing properties of the peptide
were monitored using conditioned taste aversion (CTA) testing. To
identify potential sites of action, central induction of Fos protein
expression was examined. hUcn II dose dependently reduced the quantity
and duration of responding for food and water at doses lower (0.01-1.0
&mgr;g) than that forming a CTA (10 &mgr;g). Effects were
most evident during hours 4 to 6 of the dark cycle. Meal pattern
analysis showed that hUcn II potently (0.1 &mgr;g) increased
the satiating value of food. Rats ate and drank smaller and shorter
meals without changing meal frequency. Rats also ate more slowly.
hUcn II induced Fos in regions involved in visceral sensory processing
and autonomic/neuroendocrine regulation and resembling those activated
by appetite suppressants. hUcn II is a promising neuropeptide for
investigating the role of the CRF(2) receptor in ingestive behavior.
Inoue K,et al. J Pharmacol Exp Ther
2003 Apr 1;305(1):385-393
Human urocortin II, a new CRF-related peptide, displays selective
CRF(2)-mediated action on gastric transit in rats
Human urocortin (hUcn) II is a new member of the corticotropin-releasing
factor (CRF) family that selectively binds to the CRF(2) receptor.
We investigated the CRF receptors involved in mediating the effects
of hUcn II and human/rat CRF (h/rCRF) on gut transit. Gastric emptying,
4 h after a solid meal, and distal colonic transit (bead expulsion
time) were monitored simultaneously in conscious rats. CRF antagonists
were given subcutaneously 30 min before intravenous injection of
peptides or partial restraint (for 90 min). hUcn II (3 or 10 microg/kg
i.v.) inhibited gastric emptying (by 45% and 55%, respectively)
and did not influence distal colonic transit. The CRF(2) peptide
antagonist astressin(2)-B blocked hUcn II action. h/rCRF, rat Ucn,
and restraint delayed gastric emptying while accelerating distal
colonic transit. The gastric response to intravenous h/rCRF and
restraint was blocked by the CRF(2) antagonist but not by the CRF(1)
antagonist CP-154,526, whereas the colonic response was blocked
only by CP-154,526. None of the CRF antagonists influenced postprandial
gut transit. These data show that intravenous h/rCRF and restraint
stress-induced delayed gastric emptying involve CRF(2) whereas stimulation
of distal colonic transit involves CRF(1). The distinct profile
of hUcn II, only on gastric transit, is linked to its CRF(2) selectivity.
Million M, et al. Am J Physiol Gastrointest
Liver Physiol 2002 Jan;282(1):G34-40
Differential actions of peripheral corticotropin-releasing factor
(CRF), urocortin II, and urocortin III on gastric emptying and colonic
transit in mice: role of CRF receptor subtypes 1 and 2
Peripheral CRF inhibits gastric emptying and stimulates colonic motor
function in rats. We investigated the role of CRF(1) and CRF(2)
receptors in i.p. CRF-induced alterations of gut transit in conscious
mice using selective CRF(1) and CRF(2) ligands injected i.p. Gastric
emptying 2 h after ingestion of a solid chow meal and colonic transit
(time to expel a bead inserted into the distal colon) were determined
simultaneously. Rat/human (r/h)CRF, which has CRF(1) > CRF(2)
binding affinity, decreased distal colonic transit time at lower doses
(6-12 microg/kg) than those inhibiting gastric emptying (20-60
microg/kg). Ovine CRF, a preferential CRF(1) receptor agonist (6-60
microg/kg), reduced significantly the colonic transit time without
altering gastric emptying, whereas the selective CRF(2) receptor
agonists mouse urocortin II (20-60 microg/kg) and urocortin III (120
microg/kg) inhibited significantly gastric emptying without modifying
colonic transit. The CRF(1)/CRF(2) receptor antagonist, astressin
(30-120 microg/kg), dose dependently prevented r/hCRF (20
microg/kg)-induced inhibition of gastric emptying and reduction of
colonic transit time. The selective CRF(1) receptor antagonists,
NBI-27914 (C(18)H(20)Cl(4)N(4)C(7)H(8)O(3)S) and CP-154,526
(butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]e
thylamine) (5-30 mg/kg), dose dependently blocked r/hCRF action on the
colon without influencing the gastric response, whereas the CRF(2)
receptor antagonist, antisauvagine-30 (30-100 microg/kg), dose
dependently abolished r/hCRF-induced delayed gastric emptying and had
no effect on colonic response. These data show that i.p. r/hCRF-induced
opposite actions on upper and lower gut transit in conscious mice are
mediated by different CRF receptor subtypes: the activation of CRF(1)
receptors stimulates colonic propulsive activity, whereas activation of
CRF(2) receptors inhibits gastric emptying.
Martinez V,et al. J Pharmacol Exp Ther
2002 May;301(2):611-7
Product Name |
Catalog No. |
Quantity |
USD ($) |
Urocortin III/SCP (3-40) (Human) Antibody for
Immunohistochemistry |
H-019-28 |
50µl |
$450 |
Urocortin III/SCP (3-40) (Human) Purified IgG |
G-019-28 |
200µg |
$450 |
Urocortin III/SCP (3-40) (Human) Purified IgG, Biotin Labeled |
BG-G-019-28 |
100µl |
$500 |
Urocortin III/SCP (3-40) (Human) Purified IgG, FAM Labeled |
FG-G-019-28 |
100µl |
$500 |
Urocortin III/SCP (3-40) (Human) Purified IgG, Rhodamine Labeled |
FR-G-019-28 |
100µl |
$500 |
Urocortin III/SCP (3-40) (Human) Purified IgG, R-PE Labeled |
FRP-019-28 |
100µl |
$500 |
Urocortin III/SCP (3-40) (Human) Purified IgG, Cy3 Labeled |
FC3-G-019-28 |
100µl |
$500 |
Urocortin III/SCP (3-40) (Human) Purified IgG, Cy5 Labeled |
FC5-G-019-28 |
100µl |
$500 |
|